Diabetic Retinopathy Treatment Market Size, Share, Opportunities, And Trends By Type (Proliferative DR, Non-Proliferative DR), By Management (Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), By End-User (Hospitals, Clinics, Others), And By Geography - Forecasts From 2024 To 2029

The diabetic retinopathy treatment market is anticipated to grow at a steady pace during the forecast period.

The diabetic retinopathy treatment market is fueled by several important causes, one of which is the rising incidence of diabetes worldwide. Diabetic retinopathy is a frequent consequence of diabetes that is becoming more widespread as the population affected by the disease grows. Proactive screening initiatives and more public awareness both aid in the early detection of diabetic retinopathy. The range of therapy modalities that are accessible is further being increased by technological advancements in treatment choices, including new medications and surgical treatments. The diabetic retinopathy treatment market grows and develops as a result of government initiatives and assistance, stakeholder cooperation, favourable reimbursement regulations, and patient education programmes.

Growth drivers for the diabetic retinopathy treatment market

The increasing number of people at risk for diabetes worldwide is driving up demand for efficient treatments of diabetic retinopathy. Treatment technologies that are being developed, such as novel medications and surgical techniques, provide patients and healthcare professionals with more therapeutic alternatives and draw their attention. Moreover, a key factor propelling market expansion is the focus on early diagnosis through raised awareness and screening initiatives. The market for treatments for diabetic retinopathy is dynamic, indicating continuing attempts to address the growing issues connected to this diabetes-related disease.

Growing prevalence of diabetes

The number of people at risk of diabetic retinopathy rises as diabetes becomes more common, leading to an increase in the number of diagnoses and a rise in the market for associated therapies. As published by the Australian Government, over the past 20 years, the incidence of diabetes in Australia has gradually climbed, rising from 3.3% in 2001 to 5.3% in 2022. As with other chronic illnesses, the prevalence of diabetes rises with age, it is 1.0% among those 0–44 years old and 18.7% among those 75 years of age and above. In general, the rates for men and women were comparable (5.8% and 4.9%).  The increase in cases fuels research and development, which expands the treatment options and diagnostic capabilities available to the diabetic retinopathy industry. Overall, the diabetic retinopathy treatment market's dynamics and growth trajectory are greatly impacted by diabetes.

Advancements in diagnostic technologies

The diabetic retinopathy treatment market is greatly impacted by advances in diagnostic technology, which make it possible to identify retinal abnormalities linked to diabetes earlier and with more accuracy. Newer imaging modalities, such as fundus photography and optical coherence tomography, improve the early detection of diabetic retinopathy and allow for prompt treatment. In addition to improving patient outcomes, these technical developments help drive the market by raising the need for advanced diagnostic tools and encouraging more research in the area.

Government initiatives and support

The market for diabetic retinopathy is driven by government initiatives that finance research, upgrade the healthcare system, and launch awareness programmes. Encouraging innovation and improving accessibility to care are two more ways that supportive regulatory frameworks and subsidies for sophisticated therapies contribute to market growth. For instance, The Project in India’s objective is to create and incorporate into government health systems services for the management, early identification, and prevention of diabetic retinopathy. With 24 partners, the initiative is being carried out in 53 facilities throughout 10 Indian states. Partnerships between the public and business sectors support an all-encompassing strategy that tackles issues and advances the treatment of diabetic retinopathy.

Diabetic retinopathy screening programs

Opportunistic screening is the term for DR screening that takes place when a patient comes into the ophthalmology clinic for investigations or other problems. Although it is seen to be comparatively simpler to start, its inability to exclusively target the local populace is a significant drawback. Target groups for systematic screening include all at-risk individuals. Most DR screening initiatives begin as opportunistic screening in certain healthcare settings. Although implementing comprehensive screening is challenging, it is essential in India given the nation's rising diabetes rate. Furthermore, a health systems approach is necessary for planning a comprehensive DR screening programme.

Proliferative DR is anticipated to be the fastest-growing segment

An advanced form of diabetic retinopathy called proliferative diabetic retinopathy (PDR) is defined by the development of aberrant blood vessels on the retina. Serious visual impairment or even retinal detachment may result from these brittle veins. For those with diabetes, PDR need early medical intervention to control neovascularization and avoid vision loss. This is frequently accomplished with laser treatment or anti-VEGF injections. The development of proliferative diabetic retinopathy (PDR) is closely linked to elements of poorly managed diabetes, including extended exposure to high blood sugar and hypertension. The proliferative stage of diabetes is facilitated by genetic predispositions, ethnic characteristics, and the chronic nature of the disease. The risk is also increased by oxidative stress, dyslipidemia, inflammatory processes, and postponed eye exams.

Prominent growth is anticipated in the North American region

Diabetic retinopathy is a potentially blinding condition that is on the rise in North America because of the increased prevalence of diabetes. The need for earlier identification and treatment is being driven by an aging population that is more susceptible to diabetes, as well as by improved diagnostic technologies and more awareness in countries including the USA and Canada. The industry is expanding due to favourable reimbursement rules, although obstacles like the high cost of healthcare and prescription drugs still exist. Furthermore, enhancing patient comprehension and compliance with treatment plans can have a favourable effect on market expansion.

Market Key Developments

• In November 2023, In support of the advancement of oral APX3330 for the treatment of diabetic retinopathy (DR) into Phase 3 studies based on the recently concluded Phase 2 ZETA-1 trial, Ocuphire Pharma, Inc. has announced the successful outcome of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). Ocuphire Pharma, Inc. is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercialising small-molecule therapies for the treatment of retinal and refractive eye disorders.
• In June 2023, The FDA gave the green light for Eyenuk, a global leader in real-world applications of AI Eye ScreeningTM and AI Predictive BiomarkersTM, to use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy (DR), expanding on the previously approved use of the system with Canon CR-2 AF and Canon CR-2 Plus AF cameras.
• In November 2022,  REGENXBIO Inc. published additional positive interim results from the ongoing Phase II ALTITUDE® trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edoema (CI-DME) using in-office suprachoroidal injection.

Segmentation:

• By Type
  • Proliferative DR
  • Non-Proliferative DR
• By Management
  • Anti-VEGF Therapy
  • Intraocular Steroid Injection
  • Laser Surgery
  • Vitrectomy
• By End-User
  • Hospitals
  • Clinics
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. DIABETIC RETINOPATHY TREATMENT MARKET BY TYPE

5.1. Introduction

5.2. Proliferative DR

5.3. Non-Proliferative DR

6. DIABETIC RETINOPATHY TREATMENT MARKET BY MANAGEMENT

6.1. Introduction

6.2. Anti-VEGF Therapy

6.3. Intraocular Steroid Injection

6.4. Laser Surgery

6.5. Vitrectomy

7. DIABETIC RETINOPATHY TREATMENT MARKET BY END-USER

7.1. Introduction

7.2. Hospitals

7.3. Clinics

7.4. Others

8. DIABETIC RETINOPATHY TREATMENT MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

10.1. Eyenuk Inc.

10.2. Retmarker

10.3. Boehringer Ingelheim

10.4. RetinaRisk

10.5. Retina Labs

10.6. Baxter

10.7. Nikon Healthcare

10.8. Specsavers

10.9. Ocuphire Pharma

10.10. Healthvisors

Eyenuk Inc.

Retmarker

Boehringer Ingelheim

RetinaRisk

Retina Labs

Baxter

Nikon Healthcare

Specsavers

Ocuphire Pharma

Healthvisors